May 25, 1993
Allergan Inc., a provider of eye-care and other medical products, said it has agreed to conduct joint clinical trials of drugs with Summit Technology Inc. The companies will conduct joint clinical trials of certain drugs for use after a surgical procedure known as photorefractive keratectomy. The procedure involves the use of a laser to correct eye disorders such as nearsightedness, farsightedness and astigmatism.
January 24, 2006 |
Botox maker Allergan Inc. said it was extending its $3.2-billion offer to buy breast implant maker Inamed Corp. because it had yet to get antitrust clearance from regulators. The offer is now set to expire at 8 p.m. on Feb. 7; it had been set to expire today. Irvine-based Allergan and Santa Barbara-based Inamed said they were working with the Federal Trade Commission to complete the sale of Inamed's license for Reloxin, a botulism toxin product.
August 2, 2007
Allergan Inc. posted stronger-than-expected quarterly earnings Wednesday on higher sales of prescription drugs, medical devices and its Botox anti-wrinkle product. Second-quarter profit rose to $138 million, or 45 cents a share, from $74 million, or 24 cents, a year earlier. Excluding special items, the Irvine-based company earned 54 cents a share, topping the average forecast by analysts of 3 cents, according to Reuters Estimates.
CALIFORNIA | LOCAL
June 12, 1996
The Orange County chapter of the American Red Cross has received two grants totaling $11,000 for its disaster preparedness programs. Pacific Mutual Foundation of Newport Beach made a $5,000 contribution, and Allergan Inc. of Irvine gave $6,000. Dolores Churchill, the chapter's chairwoman, said the Red Cross recently spent $30,000 to help 37 families who were left homeless when a May 19 blaze burned their Garden Grove apartment complex.
August 27, 1991
Allergan Inc. has won U.S. and Canadian marketing rights to an anti-acne medication sold in Europe by Schering AG of Germany, the company said Monday. Herbert Laboratories, the skin care division of Allergan, will begin clinical studies on the topical compound, azelaic acid, and seek FDA approval, a process expected to take at least three years, said Allergan spokesman Jeff D'Eliscu. Schering has been marketing azelaic acid as Skinoren cream in Europe, the company said.